Walter Ferlin,
CSO
Walter Ferlin obtained a PhD in Immunology from the University of California, Davis & DNAX Research Institute, Palo Alto, California, working on the use of anti-CD40 antibodies as vaccine adjuvants. As a Postdoctoral Fellow at the CNRS institute in Sophia Antipolis, France, he focused on investigating tolerance mechanisms to islet antigens in diabetic mice where he developed peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. In 2003 Walter joined Novimmune as the project leader for the development of a fully human antibody to interferon gamma. This antibody went on to become Novimmune’s first approved medicine for the treatment of primary hemophagocytic lymphohistiocytosis. Walter has also led several therapeutic bispecific antibody programs for cancer therapy now in clinical development. As Head of the Preclinical and Translational Sciences Department, Walter now oversees all preclinical and translational studies to support the pipeline of products in the immunotherapy for cancer.
|
|
|
